Rheumatoid Arthritis Trial, Recruiting NCT05365009 Sponsor: EPIMAR registry Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT05365009
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with interstitial lung disease (a condition causing scarring or inflammation in the lungs) within the last 5 years, as confirmed by a team that includes at least one lung specialist and one joint/autoimmune disease specialist
  • People whose lung scans (a detailed type of CT scan taken within the last 12 months) show certain specific changes in the lungs, such as haziness, thickening, or scarring patterns
  • People who have one of the following: a confirmed or early autoimmune/connective tissue disease; a condition called IPAF (features suggesting an autoimmune-related lung disease that doesn't fully meet the criteria for a named condition); or a positive blood test result for certain antibodies (called ANCA) linked to blood vessel inflammation, with or without other symptoms
  • People who have had a breathing function test (spirometry) done within the 6 months before joining the registry
  • People who are willing and able to sign a consent form agreeing to take part

Who may not be able to join:

  • People who are not able to attend the required follow-up appointments or complete the tests and assessments set out in the study plan
  • People who cannot be assessed by a specialist team that includes at least one lung specialist and one joint/autoimmune disease specialist
  • People whose lung disease appears to be caused by something other than an autoimmune condition — for example, workplace exposures or toxic substances — as determined by the specialist team

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Florencia Vivero, MD, Sociedad Argentina Reumatologia

Phone: 542236184381

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
EPIMAR registry
Registry
ClinicalTrials.gov
Start date
10 April 2022
Est. completion
1 April 2023

Where this trial is recruiting

🇦🇷 Argentina

Primary endpoints

Mortality; Pulmonary test functionals; Fibrosis in Computed tomography

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov